Skip to main
RAPP

RAPP Stock Forecast & Price Target

RAPP Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Rapport Therapeutics Inc has demonstrated significant momentum following its inaugural R&D Day and the positive Phase 2a data released on September 8, indicating the potential of RAP-219 in treating refractory focal onset epilepsy. The first-in-patient data from the ongoing Phase 2a study highlights meaningful reductions in seizure frequency and enhances overall daily functioning, suggesting a strong therapeutic profile. Additionally, the favorable reception from physicians and an improving reimbursement landscape point to a growing market opportunity, which bodes well for the commercial prospects of RAP-219 as it progresses toward Phase 3 trials.

Bears say

Rapport Therapeutics Inc faces a challenging path ahead due to several fundamental issues, including the potential overestimation of efficacy for its lead product, RAP-219, which may negatively impact Phase 3 trial outcomes. The company also confronts significant risks such as a competitive market with more advanced therapies, uncertainties around regulatory approval, and the necessity for additional funding to sustain its clinical development efforts. Furthermore, even if regulatory approval is achieved, the anticipated commercial adoption may be hindered by unfavorable insurance coverage and the presence of established treatments that dominate the marketplace.

RAPP has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Rapport Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Rapport Therapeutics Inc (RAPP) Forecast

Analysts have given RAPP a Strong Buy based on their latest research and market trends.

According to 5 analysts, RAPP has a Strong Buy consensus rating as of Dec 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $47.80, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $47.80, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Rapport Therapeutics Inc (RAPP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.